Gain-of-function mutations in PCSK9 lead to a phenotype typical for FH; conversely, dominant loss-of-function mutations result in an enhancement of LDLR activity and thus to lifelong reductions in plasma LDL-C and reduced risk of CHD [11••, 50–52]. The gene discussed is PCSK9; the disease is familial hyperaldosteronism.